Product
Sitravatinib Malate
1 clinical trial
1 indication
Indication
Uveal melanomaClinical trial
Phase II, Open-Label Study of Preliminary Efficacy of Sitravatinib in Combination With Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.Status: Active (not recruiting), Estimated PCD: 2023-12-31